{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T16:38:06Z","timestamp":1758040686507,"version":"3.44.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006400","name":"Alnylam Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006400","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.amjmed.2022.01.007","type":"journal-article","created":{"date-parts":[[2022,1,23]],"date-time":"2022-01-23T01:25:39Z","timestamp":1642901139000},"page":"S53-S57","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"S1","title":["Future Developments in Light Chain Amyloidosis Management"],"prefix":"10.1016","volume":"135","author":[{"given":"Mario","family":"Rodriguez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Lenihan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giampaolo","family":"Merlini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2022.01.007_bib0001","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S0002-9343(97)89487-9","article-title":"Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only","volume":"100","author":"Skinner","year":"1996","journal-title":"Am J Med"},{"key":"10.1016\/j.amjmed.2022.01.007_bib0002","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1182\/blood-2003-08-2788","article-title":"Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation","volume":"103","author":"Palladini","year":"2004","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.amjmed.2022.01.007_bib0003","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1182\/blood-2006-03-001164","article-title":"Dangerous small B cell clones","volume":"108","author":"Merlini","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.amjmed.2022.01.007_bib0004","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","article-title":"Systemic immunoglobulin light chain amyloidosis","volume":"4","author":"Merlini","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"10.1016\/j.amjmed.2022.01.007_bib0005","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1182\/blood-2011-05-355784","article-title":"The repertoire of \u03bb light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44","volume":"119","author":"Perfetti","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.amjmed.2022.01.007_bib0006","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMra023144","article-title":"Molecular mechanisms of amyloidosis","volume":"349","author":"Merlini","year":"2003","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.amjmed.2022.01.007_bib0007","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.jmb.2019.12.015","article-title":"Inherent biophysical properties modulate the toxicity of soluble amyloidogenic light chains","volume":"432","author":"Maritan","year":"2020","journal-title":"J Mol Biol"},{"issue":"17","key":"10.1016\/j.amjmed.2022.01.007_bib0008","doi-asserted-by":"crossref","first-page":"8360","DOI":"10.1073\/pnas.1817567116","article-title":"Stabilization of amyloidogenic immunoglobulin light chains by small molecules","volume":"116","author":"Morgan","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.amjmed.2022.01.007_bib0009","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1182\/bloodadvances.2020002813","article-title":"Pharmacologic targeting of plasma cell endoplasmic reticulum proteostasis to reduce amyloidogenic light chain secretion","volume":"5","author":"Rius","year":"2021","journal-title":"Blood Adv"},{"issue":"46","key":"10.1016\/j.amjmed.2022.01.007_bib0010","doi-asserted-by":"crossref","first-page":"E10839","DOI":"10.1073\/pnas.1805515115","article-title":"Bifunctional amyloid-reactive peptide promotes binding of antibody 11-1F4 to diverse amyloid types and enhances therapeutic efficacy","volume":"115","author":"Wall","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Suppl 1","key":"10.1016\/j.amjmed.2022.01.007_bib0011","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2020-143307","article-title":"Detection of systemic AL amyloidosis and differentiation of AL from ATTR using 124I-p5+14 PET imaging","volume":"136","author":"Wall","year":"2020","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.amjmed.2022.01.007_bib0012","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1182\/blood.2020006913","article-title":"Management of AL amyloidosis in 2020","volume":"136","author":"Palladini","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.amjmed.2022.01.007_bib0013","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41408-021-00444-0","article-title":"MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients","volume":"11","author":"Mellors","year":"2021","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.amjmed.2022.01.007_bib0014","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jacbts.2019.02.002","article-title":"Emerging therapeutics for the treatment of light chain and transthyretin amyloidosis","volume":"4","author":"Zhang","year":"2019","journal-title":"JACC Basic Transl Sci"},{"issue":"1","key":"10.1016\/j.amjmed.2022.01.007_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/asheducation-2017.1.1","article-title":"AL amyloidosis: from molecular mechanisms to targeted therapies","volume":"2017","author":"Merlini","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"Suppl 1","key":"10.1016\/j.amjmed.2022.01.007_bib0016","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2020-137582","volume":"136","author":"Comenzo","year":"2020","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.amjmed.2022.01.007_bib0017","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/blood-2020-139754","article-title":"Outcomes by cardiac stage in newly diagnosed AL amyloidosis: results from Andromeda","volume":"136","author":"Minemma","year":"2020","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.amjmed.2022.01.007_bib0018","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1182\/blood.2019004436","article-title":"Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study","volume":"135","author":"Sanchorawala","year":"2020","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.amjmed.2022.01.007_bib0019","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1182\/blood-2019-124244","article-title":"OP201: a phase 1\/2 study of melflufen and dexamethasone in patients with immunoglobulin light chain (AL) amyloidosis","volume":"134","author":"Palladini","year":"2019","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.amjmed.2022.01.007_bib0020","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood-2020-143180","article-title":"A phase II study of isatuximab (SAR650984) (NSC-795145) for patients with previously treated AL amyloidosis (SWOG S1702; NCT#03499808)","volume":"136","author":"Parker","year":"2020","journal-title":"Blood"},{"issue":"36","key":"10.1016\/j.amjmed.2022.01.007_bib0021","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.amjmed.2022.01.007_bib0022","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood.2019000834","article-title":"A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib","volume":"134","author":"Manwani","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.amjmed.2022.01.007_bib0023","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/13506129.2020.1798224","article-title":"Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis","volume":"28","author":"Kastritis","year":"2021","journal-title":"Amyloid"},{"issue":"5","key":"10.1016\/j.amjmed.2022.01.007_bib0024","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1182\/blood-2017-02-767467","article-title":"Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome","volume":"130","author":"Milani","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.amjmed.2022.01.007_bib0025","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1182\/blood-2017-02-767475","article-title":"AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis","volume":"130","author":"Dittrich","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.amjmed.2022.01.007_bib0026","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1002\/ajh.25940","article-title":"Refining amyloid complete hematological response: quantitative serum free light chains superior to ratio","volume":"95","author":"Muchtar","year":"2020","journal-title":"Am J Hematol"},{"issue":"Suppl 1","key":"10.1016\/j.amjmed.2022.01.007_bib0027","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1182\/blood-2020-140708","article-title":"First glimpse on real-world efficacy outcomes for 2000 patients with systemic light chain amyloidosis in Europe: a retrospective observational multicenter study by the European Myeloma Network","volume":"136","author":"Palladini","year":"2020","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.amjmed.2022.01.007_bib0028","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1073\/pnas.92.7.2959","article-title":"Interaction of the anthracycline 4\u2032-iodo-4\u2032-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis","volume":"28","author":"Merlini","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.amjmed.2022.01.007_bib0029","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/S0002-9440(10)65065-1","article-title":"4\u2032-Iodo-4\u2032-deoxydoxorubicin disrupts the fibrillar structure of transthyretin amyloid","volume":"156","author":"Palha","year":"2000","journal-title":"Am J Pathol"},{"issue":"23","key":"10.1016\/j.amjmed.2022.01.007_bib0030","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1182\/blood-2013-10-525634","article-title":"A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis","volume":"123","author":"Diomede","year":"2014","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.amjmed.2022.01.007_bib0031","doi-asserted-by":"crossref","first-page":"6610","DOI":"10.1182\/blood-2011-04-351643","article-title":"Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis","volume":"118","author":"Ward","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.amjmed.2022.01.007_bib0032","doi-asserted-by":"crossref","first-page":"e546","DOI":"10.1038\/bcj.2017.26","article-title":"Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis","volume":"7","author":"Wechalekar","year":"2017","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.amjmed.2022.01.007_bib0033","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMoa1504942","article-title":"Therapeutic clearance of amyloid by antibodies to serum amyloid p component","volume":"373","author":"Richard","year":"2015","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.amjmed.2022.01.007_bib0034","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1200\/JCO.2015.63.6530","article-title":"First-in-human phase I\/II study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction","volume":"34","author":"Gertz","year":"2016","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.amjmed.2022.01.007_bib0035","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1182\/blood-2019-124482","article-title":"Results of the phase 3 VITAL Study of NEOD001 (birtamimab) plus standard of care in patients with light chain (AL) amyloidosis suggest survival benefit for Mayo stage IV patients","volume":"134","author":"Gertz","year":"2019","journal-title":"Blood"},{"issue":"sup 1","key":"10.1016\/j.amjmed.2022.01.007_bib0036","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1080\/13506129.2017.1292900","article-title":"Interim analysis of the phase 1a\/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis","volume":"24","author":"Edwards","year":"2017","journal-title":"Amyloid"},{"issue":"Suppl 1","key":"10.1016\/j.amjmed.2022.01.007_bib0037","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1182\/blood-2018-99-118464","article-title":"Improvement in global longitudinal strain (GLS) correlates with NT-ProBNP response in patients with cardiac amyloidosis treated on a phase 1b study of anti-amyloid MAB CAEL-101","volume":"132","author":"Bhutani","year":"2018","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.amjmed.2022.01.007_bib0038","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/blood-2020-137235","article-title":"Safety, tolerability and efficacy of cael-101 in AL amyloidosis patients treated on a phase 2, open-label, dose selection study to evaluate the safety and tolerability of CAEL-101 in patients with AL amyloidosis","volume":"136","author":"Khouri","year":"2020","journal-title":"Blood"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934322000274?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934322000274?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T09:25:49Z","timestamp":1757582749000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934322000274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":38,"alternative-id":["S0002934322000274"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2022.01.007","relation":{},"ISSN":["0002-9343"],"issn-type":[{"type":"print","value":"0002-9343"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Future Developments in Light Chain Amyloidosis Management","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2022.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}